IDH1 and central nervous system cancer: Since the World Health Organization classification of central nervous system tumors incorporated molecular diagnostics into its diagnostic criteria in 2016, the need for tissue collection and molecular analysis has increased.17 We routinely performed IDH1/2, TERT promoter, and H3-3A analyses to diagnose diffuse gliomas that constitute most gliomas.